Clinical Trials Logo

Filter by:
NCT ID: NCT01589146 Recruiting - Clinical trials for Prophylaxis Given for 8±2 Days After Planned Laparoscopic

ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.

PRO-LAPS I
Start date: September 2010
Phase: Phase 3
Study type: Interventional

Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported incidence of VTE. The aim of this multicenter, randomized study is to assess the clinical benefit of extended (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for colorectal cancer.

NCT ID: NCT01583907 Recruiting - Food Allergy Clinical Trials

Nutrition in Children With Food Allergy

Start date: March 2012
Phase: Phase 0
Study type: Observational

The investigators aim to asses the effect of dieto-therapy and of nutritional counseling on the nutritional status, body growth and tolerance acquisition in children with cow's milk allergy.

NCT ID: NCT01580254 Recruiting - Tear Break-Up Time Clinical Trials

Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma

LATANOPROST
Start date: June 2011
Phase: Phase 4
Study type: Interventional

This study examines efficacy and tolerability of 3 different Latanoprost 0.005% eyedrops preparations, commercially available in Italy, in subjects affected by primary open angle glaucoma.

NCT ID: NCT01579591 Recruiting - Rectal Cancer Clinical Trials

VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer

Start date: March 2012
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase III study involving 160 patients designed to assess the efficacy of the high potency probiotic preparation VSL#3® versus placebo in increasing the pathological major response rate in patients undergoing concurrent CT and pelvic RT.

NCT ID: NCT01574261 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial

Start date: March 2012
Phase: Phase 0
Study type: Interventional

Polycystic ovary syndrome (PCOS) is associated with an increased cardiovascular risk. The aim of the study was to evaluate long-term effects of inositol on some cardiovascular risk factors in PCOS patients.

NCT ID: NCT01574053 Recruiting - Clinical trials for Huntington's Disease

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Start date: July 2012
Phase:
Study type: Observational [Patient Registry]

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.

NCT ID: NCT01572623 Recruiting - Carotid Stenosis Clinical Trials

Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting

ARMYDA-CARO
Start date: July 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of two different loading doses of Clopidogrel and a reloading of Atorvastatin in the prevention of periprocedural ischemic brain damage in patients undergoing carotid angioplasty.

NCT ID: NCT01572129 Recruiting - Clinical trials for Myocardial Infarction

Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy

Start date: November 2011
Phase: Phase 4
Study type: Interventional

Patients who developed an acute coronary syndrome despite dual antiplatelet therapy with aspirin and clopidogrel may benefit from a further dose of clopidogrel before a percutaneous coronary intervention. The aim of this study is to evaluate safety and effectiveness of clopidogrel reloading in patients on chronic clopidogrel therapy with acute coronary syndrome undergoing percutaneous coronary intervention.

NCT ID: NCT01571986 Recruiting - Clinical trials for Acute Respiratory Failure

Improving Non-invasive Ventilation

Improving NIV
Start date: February 2012
Phase:
Study type: Observational

A single center, observational, prospective study to improve knowledge about non-invasive ventilation, obtaining data about compliance, efficacy, imaging in patients who already receive non-invasive ventilation as standard of care.

NCT ID: NCT01569958 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis

Start date: July 2012
Phase: Phase 2
Study type: Interventional

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by progressive weakness and muscular atrophy due to the degeneration and loss of motor neurons, the nerve cells that, in the central nervous system (motor cortex, brainstem and spinal chord), control voluntary movement. Riluzole, the only drug approved for ALS treatment, modestly slow disease progression. Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuromodulation that is currently studied as a possible therapeutic tool for several neurological and psychiatric diseases and has been found safe and well tolerated. Based on experimental evidence in animals and human subjects, tDCS is expected to reduce motor cortex excitability and excitotoxicity, that is neuronal injury induced by excessive glutamatergic stimulation, one of postulated pathophysiological mechanisms in ALS. This study will investigate if transcranial direct current stimulation of motor cortex is useful in delaying disease progression and is well tolerated in ALS patients.